LEGN
Legend Biotech Corporation·Healthcare
18.16
0.220%(−0.04)
Market ClosedLast Updated: — ET
52W L: $16.2452W H: $45.30
LEGN NEWS
defenseworld.net
Apr 4
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of “Moderate Buy” by Brokerages
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a
defenseworld.net
Mar 15
ArrowMark Colorado Holdings LLC Has $30.61 Million Stock Holdings in Legend Biotech Corporation Sponsored ADR $LEGN
ArrowMark Colorado Holdings LLC lowered its holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 4.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 938,678 shares of the company's stock after selling 44,832 shares during the quarter. ArrowMark Colorado Holdings LLC
defenseworld.net
Mar 13
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN
Capital International Investors decreased its stake in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 13.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 941,600 shares of the company's stock after selling 140,873 shares during the quarter. Capital
seekingalpha.com
Mar 10
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 10
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights.
seekingalpha.com
Mar 2
Artisan International Small-Mid Fund Q4 2025 Performance Review
The portfolio meaningfully outperformed the MSCI EAFE Small Cap Growth Index but modestly lagged the blend MSCI ACWI ex USA SMID Index. Our portfolio, which has a structural growth orientation, has no exposure to these cyclical, capital-intensive and highly regulated market segments. On an individual company basis, Metso, Celcuity and LivaNova were the largest Q4 contributors.
